Last week we outlined the impact of risk-based monitoring (RBM) on clinical trials and technology’s role in transforming the way trials are done. In Part Two of our interview with Andy Lawton, the Global Head of Clinical Data Management at Boehringer Ingelheim, Andy discusses the metrics useful for RBM, its adoption in the life sciences industry, and what’s to come next with this evolving concept. 

from Forbes – Tech http://ift.tt/1Wpr1bB
via IFTTT